London-based Labgenius Raises Over €40.1 Million To Further Develop Its Ml-driven Antibody Discovery Platform

LabGenius, a London-based drug discovery company, has closed a Series B financing round of over €40.1 million. The company uses machine learning and a smart robotic platform to rapidly identify high-performing antibodies for therapeutic use. The funding will be used to expand the platform and progress a pipeline of multispecific antibodies towards clinical trials.